Universal $2.5 Bn Ventricular Assist Devices Market Size | Industry Statistics with Major Eminent Leaders: Abiomed, Boston Scientific Corporation, Biotronik SE & Co. KG, LivaNova PLC, Medtronic plc, Berlin Heart GmbH, ReliantHeart, HeartWare International

A Research Study Titled, “Ventricular Assist Devices Market by Product, Application, Design, and End User - Global Industry Analysis and Forecast to 2025” published by Crystal Market Research, states that the VADs market is projected to be around $2.5 billion by 2025.

A Ventricular Assist Device or a VAD is a mechanical pump. When a ventricle of heart (generally left) stops working properly, a VAD has to be attached to theventricle to supply blood through the body. Ventricles constitute the lower chamber of the heart. VAD support heart function and blood flow even in cases of heart failure. It includes a pump that is attached to the heart, an external controller, a cable to connect the pump with controller and a power source to run the device.

Access Sample Copy of This (Ventricular Assist Devices Market) Report: https://www.crystalmarketresearch.com/report-sample/HC0624 .

The global VADs market is highly consolidated with major players acquiring smaller vendors. Some of the major companies include Abiomed, Inc., Boston Scientific Corporation, Biotronik SE & Co. KG, LivaNova PLC, Medtronic plc, Berlin Heart GmbH, ReliantHeart Inc., HeartWare International, Inc., Jarvik Heart, Inc., and St. Jude Medical, Inc. (recently acquired by Abbott Laboratories).

A ventricular assistive device (VAD) is an implantable mechanical pump that facilitates pumping of blood from lower chambers of the heart to rest of the body. The device aids the patients affected by congestive heart failure to support normal blood pumping function of the heart while the patient is waiting for a transplant. Congestive heart failure is a chronic condition in which the heart is unable to pump blood to different parts of the body. As per American Heart Association, more than six million Americans are living with heart failure and 10% of them are having advanced heart failure. However, therapies such as LVADs are dramatically improving the quality life of people with advanced heart failure. These patients benefit from LVADs; while waiting for a heart transplant or can obtain long-term support from LVADs if they are not candidates for a transplant.

Left ventricular assist devices (LVADs) segment accounted for almost three-fourth of the global market in 2016. This large share is due to its advantages to support the function of left, right, or both heart ventricles. LVADs are used to support patient’s heart until it recovers or while the patient is waiting for a heart transplant.

Bridge-to-transplantation (BTT) and bridge-to-decision(BTD) therapies segment leads the global VADs market. This segment accounted for more than half of the overall market in 2016. BTT therapy implants VADs for heart management in patients who have had severe heart failure and are waiting for heart transplant; while BTD therapy implants VADs in patients for whom the physician is not sure if the patient is an ideal candidate for a transplant.

Percutaneous VADs (pVADs) are specific types of VADs. PVADs are less invasive in nature and differ in design and use as compared to traditional VADs. These are alternative to a traditional VAD or IABP (intra-aortic balloon pump) for short-term hemodynamic support. These are used during emergent procedures for patients in acute heart failure due to left ventricular dysfunction or cardiogenic shock.

North America accounted for more than half of the overall market in 2016. This large share is attributed to a number of factors such the presence of advanced healthcare infrastructure and increased adoption of technologically advanced products. Asia Pacific is expected to witness lucrative market growth over the forecast period, due to the availability of untapped and unsaturated markets coupled with rising demand for VADs. Rapid economic development along with increasing patient awareness levels is a major avenue for the companies in the VADs industry.

Browse Complete (Ventricular Assist Devices Market) Report with ToC: https://www.crystalmarketresearch.com/report/ventricular-assist-devices-market .

Ventricular Assist Devices - By Region:

North America - U.S, Canada, Mexico
Europe - Germany, France, UK, Italy, Spain, Rest of Europe
Asia-Pacific - Japan, China, Australia, India, South Korea, Rest of Asia Pacific
Rest of the World - Brazil, South Africa, Saudi Arabia, United Arab Emirates, Others

Ventricular Assist Devices - Regional Outlook and Trend Analysis:

In 2016, North America dominated the global VADs market with highest market share. This dominance can be attributed to the presence of huge patient population along with high adoption of technologically advanced products and high disposable income of the population. With the presence of sophisticated healthcare infrastructure the market will show significant growth over the forecast period.

Asia-Pacific will exhibit fastest growth during the forecast period due to rising number of cases related to diabetic disorders. Promotion of medical tourism activities by governments in various emerging economies to offer cost effective treatment to foreign patients is set to boost the market growth of VADs.

Ventricular Assist Devices - By Product:

Right Ventricular Assist Devices (RVADs)
Left Ventricular Assist Devices (LVADs)
Biventricular Assist Devices (BIVADs)

Ventricular Assist Devices - By Application:

Destination Therapy
BTT and BTD Therapies
BTR Therapy

Ventricular Assist Devices - By Design:

Implantable VADs
Percutaneous VADs

Ventricular Assist Devices - By End User:

Ambulatory Surgical Centers
Hospitals

Check Best Offer of This (Ventricular Assist Devices Market) Report: https://www.crystalmarketresearch.com/check-discount/HC0624 .

Ventricular Assist Devices - ToC:

CHAPTER 9. Company Profiles -

9.1. Abiomed, Inc.
9.1.1. Business Overview
9.1.2. Product Portfolio
9.1.3. Key Financials
9.1.4. Strategic Developments

9.2. Boston Scientific Corporation
9.2.1. Business Overview
9.2.2. Product Portfolio
9.2.3. Key Financials
9.2.4. Strategic Developments

9.3. Berlin Heart GmbH
9.3.1. Business Overview
9.3.2. Product Portfolio
9.3.3. Key Financials
9.3.4. Strategic Developments

9.4. Biotronik SE & Co. KG
9.4.1. Business Overview
9.4.2. Product Portfolio
9.4.3. Strategic Developments

9.5. LivaNova PLC
9.5.1. Business Overview
9.5.2. Product Portfolio
9.5.3. Key Financials
9.5.4. Strategic Developments

9.6. Medtronic, Inc.
...

Reason to Buy -

- Highlights key business priorities in order to assist companies to realign their business strategies.

- The key findings and recommendations highlight crucial progressive industry trends in the Ventricular Assist Devices market, thereby allowing players to develop effective long term strategies.

- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to products, segmentation and industry verticals.

Buy Now This Report: https://www.crystalmarketresearch.com/checkout/HC0624 .

TO BE Continued…

About Crystal Market Research:

Crystal Market Research is a U.S. based market research and business intelligence company. Crystal offers one stop solution for market research, business intelligence, and consulting services to help clients make more informed decisions. It provides both syndicated as well as customised research studies for its customers spread across the globe. The company offers market intelligence reports across a broad range of industries including healthcare, chemicals & materials, technology, automotive, and energy.

Contact Us:
Judy
304 South Jones Blvd, Suite 1896,
Las Vegas NV 89107,
United States
Toll Free: +1-888-213-4282
Email: sales@crystalmarketresearch.com

This release was published on openPR.